Alveolar soft part sarcoma
MONDO:0011655An alveolar soft part sarcoma occurring in adults. The most common site of involvement is the extremity, particularly the deep soft tissues of the thigh.
Also known as: ASPS, adult alveolar soft Part sarcoma, adult alveolar soft part sarcoma, adult alveolar soft-Part sarcoma, alveolar soft Part sarcoma, alveolar soft part sarcoma, alveolar soft part sarcoma (disease), alveolar soft-part sarcoma
2839 clinical trials for this condition and its sub-types, 20 tagged with Alveolar soft part sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Alveolar soft part sarcoma
-
Cervical alveolar soft part sarcoma 0 trials
-
Vulvar alveolar soft part sarcoma 0 trials
-
Can a Patient's own immune cells be engineered to fight a rare sarcoma?
Cure OngoingThis trial tests a personalized cell therapy called GCAR1 in a single patient with metastatic alveolar soft part sarcoma (ASPS) that has relapsed and cannot be surgically removed. The therapy uses the patient's own immune cells, engineered to recognize and attack cancer cells dis…
Early phase 1 • Sponsor: University of Calgary • Aim: Cure
Last updated Aug 06, 2026 00:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Immunotherapy combo shows promise against rare sarcoma
Disease control OngoingThis phase 2 trial tests the immunotherapy drug atezolizumab, alone or with bevacizumab, in 63 people with advanced alveolar soft part sarcoma that cannot be surgically removed. Atezolizumab helps the immune system attack cancer cells, while bevacizumab cuts off the tumor's blood…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug duo takes on rare sarcomas
Disease control OngoingThis phase 2 trial tests whether combining NKTR-214 and nivolumab can shrink or control advanced sarcoma that has spread. About 88 people aged 12 and older with certain sarcoma types will receive both drugs every three weeks. The main goal is to see how many patients have their t…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Desperate hope: one patient gets custom immune cells for rare cancer
Disease control OngoingThis early-phase trial tests a one-of-a-kind cell therapy called GCAR1 in a single patient with advanced alveolar soft part sarcoma, a rare cancer that has spread. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells that carry a specific…
Early phase 1 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC